Methotrexate Treatment for Rheumatoid Arthritis in Poland: Retrospective Analysis of Patients in Routine Clinical Practice

The study reviewed the use of Methotrexate (MTX) in treating rheumatoid arthritis (RA) in Poland, analyzing data from 1957 patients across 100 rheumatologists. MTX was used by 91% of patients, with 80% continuing treatment either as monotherapy or with other DMARDs. The therapy typically began within 6 months of diagnosis, with oral administration being most common. Dose adjustments were frequent, primarily due to lack of efficacy or adverse effects like nausea, vomiting, and hair loss. The initial dose was usually 10-15 mg/week, with some patients increasing to 25 mg/week. Treatment interruption occurred in 21% of patients, mainly due to intolerance. Over half of the patients achieved remission or low disease activity within 3-6 months. The study concluded that MTX is effective when used according to current recommendations, but regular control visits are necessary to optimize therapy.